Essen

• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small … Halted
  2023-503298-39-00 5 2024-06-13 Metastatic Non-Small Cell Lung Cancer (mNSCLC)
• A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2) Halted
  2023-507820-22-00 3 2024-05-22 Myasthenia gravis (MG)
• A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulator … Halted
  2024-512626-28-00 5 2024-03-28 Duchenne Muscular Dystrophy
• A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine … Halted
  2023-505829-14-00 5 2023-12-22 First recurrence glioblastoma
• Study to assess the safety and expression of RO7494222 (SRP-9001) in participants under the age of 4 with Duchenne muscular dystrophy Halted
  2023-509901-57-00 4 2023-10-26 Duchenne Muscular Dystrophy
• The NeoTRACK Trial – Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – Dissection of IO efficacy in NSCLC by longitudinal tracKing: a … Halted
  2022-501322-38-00 4 2023-05-26 Non-small cell lung cancer (NSCLC)
• A Phase I/II study of DYP688 treatment alone in patients with eye cancer and other types of cancers of the skin and mucosal membranes in the … Halted
  2023-509451-14-00 7 2022-11-01 Metastatic uveal melanoma
• A Phase 2/3 Study in Adult and Pediatric Participants with SCD Suspended
  2023-508766-14-00 10 Sickle Cell Disease
• Neoadjuvant Lu-PSMA radioligand therapy and Ipilimumab in men with very high-risk prostate cancer (NEPI) Ended
  2024-514386-19-00 3 2025-08-25 Patients with very high-risk prostate cancer (as defined by a total Gl
• Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection Ended
  2024-519856-94-00 4 2025-08-18 Cystic fibrosis
• A study to investigate safety of INT2104 infusions in participants aged 18 years of age and older who have B-cell cancers that came back aft … Ended
  2023-509132-26-00 1 2025-08-08 Refractory/Relapsing B-Cell Malignancies
• A Phase 2 Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2024-516889-11-00 4 2025-05-21 non-small cell lung cancer (NSCLC)
• A long-term trial to learn about the safety of carbetocin as treatment for uncontrollable hunger in people with Prader-Willi Syndrome Ended
  2023-506201-19-00 5 2025-04-28 Hyperphagia related behaviour associated with Prader-Willi Syndrome (P
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended
  2024-512505-66-00 10 2025-03-03 HIV-1 Infection
• A Study to Understand the ability and safety of GDC-8264 in Preventing kidney Injury and Major Adverse Kidney Events following Heart Surgery Ended
  2024-513125-23-00 4 2025-02-28 Patients with moderate to high risk for cardiac surgery associated- ac
• Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults with Type 2 Diabetes M … Ended
  2024-512562-34-00 4 2025-02-24 Type 2 Diabetes Mellitus
• A weight loss study evaluating subcutaneous treatment withAZD9550 and AZD6234 in combination, against placebo or each of the drugs alone Ended
  2024-516176-15-00 4 2025-02-24 Investigating obesity or overweight condition correlated to many co-mo
• An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination wi … Ended
  2024-512670-10-00 9 2025-02-13 Unresectable or Metastatic Melanoma
• A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or togethe … Ended
  2023-508998-85-00 1 2025-01-28 Metastatic pancreatic ductal adenocarcinoma (mPDAC)
• A trial to learn how a trial drug called carbetocin works in reducing uncontrollable hunger in people with Prader-Willi syndrome Ended
  2023-506200-24-00 5 2025-01-10 Hyperphagia related behaviour associated with Prader-Willi Syndrome (P
• L19IL2/L19TNF in patients with non-melanoma skin cancer. Ended
  2024-518530-92-00 4 2024-12-09 Patients with high-risk, locally advanced (non-metastatic, node negati
• Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and … Ended
  2024-517340-61-00 5 2024-11-19 Patients after curative intent resection of cholangiocarcinoma (intrah
• A Phase 1/2 Study of VX-522 in Subjects with Cystic Fibrosis Ended
  2023-504786-23-00 7 2024-11-18 Cystic Fibrosis
• Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat … Ended
  2023-508474-29-00 4 2024-10-30 Dermatitis, Atopic

Showing 745–768 of 965 trials